| COMPANY |
Liquidia Technologies is developing highly precise particle-based vaccines and therapeutics for the prevention and treatment of human disease. Combining a deep understanding of particle-based drug development with breakthrough small molecule and biological therapeutics, Liquidia is engineering vaccines and therapies that have the potential to dramatically improve the quality of human life. The company was founded in 2004 and is located in Research Triangle Park, North Carolina.
Learn more > |
|
| PRODUCT PLATFORM |
Utilizing a novel platform known as PRINT® technology, Liquidia is designing highly specific carriers for delivery of small molecules and biological cargos. This breakthrough platform technology makes it possible for the first time to design vaccines and therapies with precise control of particle size, shape, and composition.
Learn more >
|
|
| RECENT NEWS |
February 18, 2010
Liquidia Names Dr. Frank Malinoski as Chief Medical Officer  Details
February 8, 2010
Liquidia CEO to speak at CED Biotech 2010 Conference Details
January 19, 2010
Liquidia raises $20 million Series C financing Details
December 16, 2009
Liquidia receives $3MM NIST-TIP Award Details
September 24, 2009
Liquidia Founder Receives NIH Pioneer Award Details
|
| |
|
